Adenoviral Vectors for Gene Therapy

David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.

• 1. Adenovirus Structure2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms3. Adenovirus Replication4. Adenoviral Vector Construction I: Mammalian Systems5. Adenoviral Vector Construction II: Bacterial Systems6. Upstream Bioprocess for Adenovirus Vectors7. Propagation of Adenoviral Vectors: Use of PER.C6™ Cells8. Purification of Adenovirus9. Targeted Adenoviral Vectors I: Transductional Targeting10. Targeted Adenoviral Vectors III: Transcriptional Targeting11. Adenoviral Vector Targeting via Mitigation of Liver Sequestration12. Molecular Design of Oncolytic Adenoviruses13. Conditionally Replicative Adenoviruses—Clinical Trials14. Innate Immune Response to Adenovirus Vector Administration In Vivo15. Antibodies against Adenoviruses16. Methods to Mitigate Immune Responses to Adenoviral Vectors17. Helper-Dependent Adenoviral Vectors18. Hybrid Adenoviral Vectors19. Xenogenic Adenoviral Vectors20. Engineering Chimeric Adenoviruses: Exploiting Virus Diversity for Improved Vectors, Vaccines, and Oncolytics1. Introduction22. Adenoviral Vectors Vaccine: Capsid Incorporation of Antigen23. Utility of Adenoviral Vectors in Animal Models of Human Disease I: Cancer24. In Situ Vaccination with Adenoviral Vectors to Treat Cancer25. Utility of Adenoviral Vectors in Animal Models of Human Disease II: Genetic Disease26. Adenoviral Vectors for Pulmonary Disease (Pulmonary Vascular Disease)27. Utility of Adenoviral Vectors in Animal Models of Human Disease III: Acquired Diseases28. Animal Models of Gene Therapy for Cardiovascular Disease29. Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy30. Adenoviral Vectors for RNAi Delivery31. Imaging and Adenoviral Gene Therapy32. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective